# Iconic Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iconic-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.iconictherapeutics.com
- Total disclosed funding: $64M
- Latest round: Series C (Aug 9, 2016)
- Investors on record: 10

## About

Iconic Therapeutics, Inc. is a biotechnology company focused on developing innovative solutions aimed at addressing unmet medical needs within the healthcare sector.Founded in 2002 and headquartered in San Francisco, US, Iconic Therapeutics, Inc. specializes in biopharmaceuticals that target specific diseases with precision. The company has undergone a strategic focus on developing targeted therapies and has raised a total of USD 13.030 mn, with its most recent funding round being a Series B on April 15, 2019. William Greene serves as the CEO of the company.Iconic Therapeutics, Inc. specializes in innovative biopharmaceutical products aimed at addressing specific medical needs. Its core offerings are developed to enhance therapeutic efficacy, particularly in ophthalmology, and focus on providing solutions to critical patient challenges. The company serves a diverse clientele that includes healthcare providers and institutions primarily across North America, Europe, and parts of Asia. Over recent years, Iconic has introduced several significant products that position it strategically within the healthcare market.Revenue generation for Iconic Therapeutics, Inc. is primarily structured through partnerships with healthcare institutions, product sales, and potential collaboration agreements. The pricing framework typically involves clients purchasing therapeutic solutions outright, ensuring a stable cash flow from various healthcare partners. Revenue is derived through initial sales as well as potential future royalties on successful product applications, ensuring financial sustainability.Iconic Therapeutics, Inc. is focused on expanding its product pipeline with new therapies aimed at addressing unmet medical conditions, with anticipated launches slated within the next few years. The company is also exploring market expansion strategies into Europe and Asia by 2025 to increase its global presence. The recent Series B funding of USD 13.030 mn will be utilized to support the development of new products and enhance market entry efforts, aiming to bolster the company's growth trajectory in the coming years.

## Funding rounds

- Series C, Aug 9, 2016, $10M — HBM Partners, H.I.G. BioHealth Partners, OUP (Osage University Partners), MPM BioImpact, Lundbeckfond Ventures, Cormorant Asset Management, Xeraya Capital
- Series C, Dec 24, 2015, $38M — H.I.G. Capital, HBM Partners, OUP (Osage University Partners), MPM BioImpact, Lundbeckfond Ventures, Cormorant Asset Management
- Series B, Apr 14, 2014, $13M — H.I.G. BioHealth Partners, MPM BioImpact, Lundbeckfond Ventures
- Series C, Jan 7, 2009, $2.5M — Elm Street Ventures, New Haven Pharmaceuticals Inc.

## Investors

- Elm Street Ventures (https://capitalatlas.ai/funds/elm-street-ventures) — Series C
- New Haven Pharmaceuticals Inc. — Series C
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series B, Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B, Series C
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series B, Series C
- H.I.G. Capital (https://capitalatlas.ai/funds/h-i-g-capital) — Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Xeraya Capital (https://capitalatlas.ai/funds/xeraya-capital) — Series C